BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
04/09/2021
Initial Lawsuit
04/09/2021
Lawsuit Progression
07/13/2021
Investigation regarding 3D Systems’ statements about its internal controls over financial reporting.
03/02/2021
3D Systems announces it will delay filing of its annual report because of “the presentation of cash flows associated with the divestiture process for its Cimatron and GibbsCam software businesses.” The company adds that “in the course of preparing its financial results for the fourth quarter and full year 2020, the company discovered certain internal control deficiencies” and that “as a result, the company will report material weaknesses in internal controls in its fiscal 2020 Annual Report on Form 10-K.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$31.17 | $38.79 | $-7.62 | -19.64% |
This is a federal securities class action on behalf of all persons and entities who purchased the publicly traded securities of 3D Systems from May 6, 2020 to March 1, 2021.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(1) 3D Systems lacked proper internal controls over financial reporting;
(2) as a result, 3D Systems’ public statements were materially false and/or misleading at all relevant times.
07/13/2021
The court issued an order appointing the lead plaintiff and lead counsel.
09/13/2021
This is a federal securities class action on behalf of all persons and entities that purchased the publicly-traded common stock of 3DSC from May 6, 2020, to March 5, 2021.
Operative complaint
05/16/2022
A motion to dismiss was filed with the court.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.